Key result
Bortezomib linked to acute, partially reversible cardiotoxicity with an LVEF drop to 15%.
Why the study?
Proteasome inhibitors like bortezomib are not commonly associated with cardiotoxicity in patients without pre-existing cardiac dysfunction or other cardiotoxic agents, creating uncertainty about their cardiac risks.
Design
Case report
Follow-up
Hours after third bortezomib treatment
Authors
Loading...
Bortezomib may cause acute LV dysfunction in ESRD without prior heart disease; leaves open need for prospective monitoring studies.
Case Report (n=1)
Bortezomib therapy may cause acute, partially reversible left ventricular dysfunction, highlighting the importance of baseline and serial cardiac monitoring in patients receiving proteasome inhibitors.
Meseeha et al. (2015) conducted a case report in IgG kappa myeloma (n=1). Bortezomib was evaluated on Development of acute left ventricular dysfunction. A 66-year-old woman with end-stage renal disease developed acute, partially reversible left ventricular dysfunction with an ejection fraction drop from 55% to 15% after her third dose of bortezomib.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: